Two things have changed in the last twelve months that every New Yorker considering telepsychiatry should understand. First, the DEA moved toward finalizing its long-awaited telemedicine rules for controlled substances by the end of 2025. Second, New York's Office of Mental Health quietly tightened its parity enforcement, which means private insurers can no longer hide behind narrow networks the way they used to.

Both changes affect how — and from whom — you can get an ADHD diagnosis, an anxiety prescription, or ongoing psychiatric care without leaving your apartment in Brooklyn or your office in Manhattan. Here is what is actually different in 2026, and what has not changed.

The DEA rules: the short version

What changed after the COVID flexibilities ended

For three years after the COVID public health emergency ended, telehealth providers operated under temporary flexibilities that let them prescribe Schedule II–IV controlled substances (Adderall, Vyvanse, Xanax, Klonopin, Suboxone) entirely over video, with no in-person visit required.

Those flexibilities have been progressively narrowed, with the proposed permanent framework boiling down to this:

For most Schedule III–V controlled substances (including buprenorphine for opioid use disorder), you can be prescribed via telehealth indefinitely, as long as the prescriber follows certain documentation requirements.
For Schedule II stimulants — meaning Adderall, Vyvanse, and Concerta — the latest framework moves toward requiring at least one in-person evaluation within the first six months of starting medication. Exceptions exist for patients of providers who already had an established relationship before late 2025, and the exact terms continue to evolve as the rule is finalized.

What this means for New Yorkers in practice

What this means in practice: if you are a New Yorker seeking an ADHD evaluation, choose a telepsychiatry service that has a physical office in New York or a partnership with one.

Several large platforms now operate hybrid clinics in Manhattan, Brooklyn, and Long Island specifically to satisfy this requirement.

Finding the right kind of prescriber

Who can actually prescribe in New York

"Psychiatrist" gets used loosely online. In New York, the providers who can prescribe psychiatric medication via telehealth are:

Psychiatrists (MD or DO) — Four years of medical school plus four years of psychiatry residency. The gold standard for complex cases, treatment-resistant depression, and patients on multiple medications.
Psychiatric Mental Health Nurse Practitioners (PMHNP) — Master's or doctoral level with specialized psychiatric training. New York grants PMHNPs broad prescriptive authority, including controlled substances under the state's NP scope rules. Often more available than MDs.
Primary Care Physicians — Many internists and family doctors will prescribe SSRIs, SNRIs, and basic anxiety medications themselves rather than referring out. For straightforward depression or generalized anxiety, this is often the fastest path.

Therapists cannot prescribe — even if it looks like they can

Therapists (LCSW, LMHC, LMFT) cannot prescribe in New York. If a platform pairs you with a "therapist" but promises a prescription, dig deeper — there is a prescriber somewhere in that workflow, and you should know who.

Insurance: what New York's parity law actually does

Parity is enforced — but network status still varies

New York's mental health parity law is among the strongest in the country. Private insurers (Aetna, Cigna, UnitedHealthcare, EmblemHealth, Empire BlueCross, Healthfirst) are required to cover psychiatric telehealth at the same rate as in-person — and at the same rate as physical health visits.

That does not mean every psychiatrist on every platform is in your network.

Two things to verify before booking

Two things to verify before booking:

Network status. Look up the prescriber's NPI, then call your insurer. The platform's "in-network" claim is sometimes wrong, especially for newer providers.
Place of service code. Telepsychiatry should be billed with POS 10 (patient at home) or POS 02 (other telehealth). Some plans pay differently depending on the code, even for the same service.

Medicaid is fully covered, but the network is smaller

For New Yorkers on Medicaid (managed by Fidelis, Healthfirst, MetroPlus, and others), telepsychiatry is fully covered — but the network of in-network telepsychiatrists is genuinely smaller than for commercial insurance. The state Office of Mental Health publishes a directory of Medicaid-accepting providers that is worth cross-referencing.

Realistic timelines and costs

Rough 2026 NYC pricing

Prices vary widely. As a rough guide for New York City in 2026:

Initial psychiatric evaluation, out-of-pocket: $250–$600.
Follow-up medication management visit, out-of-pocket: $100–$250.
With in-network insurance: typically $20–$60 copay per visit.
Wait time for a first appointment: 5–14 days for most platforms; longer for highly specialized care like geriatric or perinatal psychiatry.

Before you book — a short checklist

Four things to confirm

Verify the prescriber's NPI and that they are actively licensed in New York State.
If you will need a Schedule II stimulant, confirm the platform has an in-person option in New York.
Call your insurer; don't rely on the platform's network claim.
Ask whether you will see the same prescriber for follow-ups, or whether you will be rotated through whichever clinician is available.

Why continuity is non-negotiable

The last point matters more than people realize. Continuity of care — seeing the same psychiatrist across multiple visits — is one of the strongest predictors of good outcomes in psychiatric treatment, and some high-volume platforms quietly route you to whoever has an open slot rather than building a real relationship.

Disclaimer: Medication, dosage, and treatment decisions must be made with a licensed clinician who has reviewed your full medical history. This article does not constitute medical advice. If you are in crisis, call or text 988.

Virtual Psychiatrists in New York: ADHD, Anxiety, and What the New DEA Rules Actually Mean for You